Introduction Ribonucleic acid (RNA) therapeutics are a new class of drugs whose importance is highlighted by the growing number of molecules in the clinic. Sources of data We focus on RNA therapeutics for neurogenetic disorders, which are broadly defined as diseases with a genetic background and with at least one clinical sign affecting the nervous system. A systematic search identified 14 RNA drugs approved by FDA and many others in development. Areas of agreement The field of RNA therapeutics is changing the therapeutic scenario across many disorders. Areas of controversy Despite its recent successes, RNA therapeutics encountered several hurdles and some clinical failures. Delivery to the brain represents the biggest challenge. Growing points The many advantages of RNA drugs make the development of these technologies a worthwhile investment. Areas timely for developing research Clinical failures stress the importance of implementing clinical trial design and optimizing RNA molecules to hold the promise of revolutionizing the treatment of human diseases.

RNA therapeutics for neurological diseases / Brentari, Ilaria; Zadorozhna, Mariia; Denti, Michela Alessandra; Giorgio, Elisa. - In: BRITISH MEDICAL BULLETIN. - ISSN 0007-1420. - ELETTRONICO. - 2023:(2023), pp. 1-12. [10.1093/bmb/ldad010]

RNA therapeutics for neurological diseases

Brentari, Ilaria
Primo
;
Denti, Michela Alessandra
;
2023-01-01

Abstract

Introduction Ribonucleic acid (RNA) therapeutics are a new class of drugs whose importance is highlighted by the growing number of molecules in the clinic. Sources of data We focus on RNA therapeutics for neurogenetic disorders, which are broadly defined as diseases with a genetic background and with at least one clinical sign affecting the nervous system. A systematic search identified 14 RNA drugs approved by FDA and many others in development. Areas of agreement The field of RNA therapeutics is changing the therapeutic scenario across many disorders. Areas of controversy Despite its recent successes, RNA therapeutics encountered several hurdles and some clinical failures. Delivery to the brain represents the biggest challenge. Growing points The many advantages of RNA drugs make the development of these technologies a worthwhile investment. Areas timely for developing research Clinical failures stress the importance of implementing clinical trial design and optimizing RNA molecules to hold the promise of revolutionizing the treatment of human diseases.
2023
Brentari, Ilaria; Zadorozhna, Mariia; Denti, Michela Alessandra; Giorgio, Elisa
RNA therapeutics for neurological diseases / Brentari, Ilaria; Zadorozhna, Mariia; Denti, Michela Alessandra; Giorgio, Elisa. - In: BRITISH MEDICAL BULLETIN. - ISSN 0007-1420. - ELETTRONICO. - 2023:(2023), pp. 1-12. [10.1093/bmb/ldad010]
File in questo prodotto:
File Dimensione Formato  
Brentari_2023.pdf

Solo gestori archivio

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 499.46 kB
Formato Adobe PDF
499.46 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/379349
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact